Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.63 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.63 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.63 |
| ▸ | ACHE | P22303 | 3/20 | 0.63 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.63 |
| ▸ | TACR2 | P21452 | 2/20 | 0.63 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.63 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | SHBG | P04278 | 1/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.63 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.63 |
| ▸ | HTR2C | P28335 | 1/20 | 0.63 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.63 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.63 |
| ▸ | TST | Q16762 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2686704 | 1.00 | ESR1 (0.63) | ESR1ADRA2ASLC6A2ACHEADORA3 | |
| SCHEMBL2323477 | 1.00 | ESR1 (0.63) | ESR1ADRA2ASLC6A2ACHEADORA3 | |
| SCHEMBL5536586 | 0.98 | ESR1 (0.59) | ESR1ADRA2ASLC6A2ACHEADORA3 | |
| SCHEMBL4967337 | 0.91 | ESR1 (0.62) | ESR1ADRA2ASLC6A2ACHEADORA3 | |
| SCHEMBL8398450 | 0.88 | ESR1 (0.77) | ESR1ADRA2ASLC6A2ACHEADORA3 | |
| SCHEMBL9165397 | 0.88 | ESR1 (0.77) | ESR1ADRA2ASLC6A2ACHEADORA3 | |
| SCHEMBL1447579 | 0.88 | ESR1 (0.77) | ESR1ADRA2ASLC6A2ACHEADORA3 | |
| SCHEMBL2777921 | 0.88 | ESR1 (0.77) | ESR1ADRA2ASLC6A2ACHEADORA3 | |
| SCHEMBL9166790 | 0.88 | ESR1 (0.77) | ESR1ADRA2ASLC6A2ACHEADORA3 | |
| SCHEMBL7784766 | 0.88 | ESR1 (0.77) | ESR1ADRA2ASLC6A2ACHEADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10265693-B2 | Particles, particle dispersion, particle-dispersed resin composition, producing method therefor, resin molded article, producing method therefor, catalyst particles, catalyst solution, catalyst composition, catalyst molded article, titanium complex, titanium oxide particles and producing method therefor | NITTO DENKO CORPORATION (JP) | 2019-04-23 | — | — | US | disclosed |
| CN-104341787-B | Particle, particle dispersion, particle dissipating resin composition, its manufacture method, resin molded body, its manufacture method | 日东电工株式会社 | 2018-02-16 | — | — | CN | disclosed |
| US-20170189895-A1 | PARTICLES, PARTICLE DISPERSION, PARTICLE-DISPERSED RESIN COMPOSITION, PRODUCING METHOD THEREFOR, RESIN MOLDED ARTICLE, PRODUCING METHOD THEREFOR, CATALYST PARTICLES, CATALYST SOLUTION, CATALYST COMPOSITION, CATALYST MOLDED ARTICLE, TITANIUM COMPLEX, TITANIUM OXIDE PARTICLES AND PRODUCING METHOD THEREFOR | NITTO DENKO CORPORATION (JP) | 2017-07-06 | — | — | US | disclosed |
| US-20160222194-A1 | PARTICLES, PARTICLE DISPERSION, PARTICLE-DISPERSED RESIN COMPOSITION, PRODUCING METHOD THEREFOR, RESIN MOLDED ARTICLE, PRODUCING METHOD THEREFOR, CATALYST PARTICLES, CATALYST SOLUTION, CATALYST COMPOSITION, CATALYST MOLDED ARTICLE, TITANIUM COMPLEX, TITANIUM OXIDE PARTICLES AND PRODUCING METHOD THEREFOR | NITTO DENKO CORPORATION (JP) | 2016-08-04 | — | — | US | disclosed |
| CN-102822098-B | Particle, particle dispersion liquid, particle-dispersed resin composition, method for producing same, resin molded article, method for producing same, catalyst particle, catalyst liquid, catalyst composition, catalyst molded article, titanium complex, titanium oxide particle, and method for producing same | NITTO DENKO CORP. (JP) | 2015-11-25 | — | — | CN | disclosed |
| CN-102532162-B | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMA CO LTD | 2015-05-27 | — | — | CN | disclosed |
| US-20150065340-A1 | PARTICLES, PARTICLE DISPERSION, PARTICLE-DISPERSED RESIN COMPOSITION, PRODUCING METHOD THEREFOR, RESIN MOLDED ARTICLE, PRODUCING METHOD THEREFOR, CATALYST PARTICLES, CATALYST SOLUTION, CATALYST COMPOSITION, CATALYST MOLDED ARTICLE, TITANIUM COMPLEX, TITANIUM OXIDE PARTICLES AND PRODUCING METHOD THEREFOR | NITTO DENKO CORPORATION (JP) | 2015-03-05 | — | — | US | disclosed |
| CN-104341787-A | PARTICLES, PARTICLE DISPERSION SOLUTION, PARTICLE DISPERSION RESIN COMPOSITION, PRODUCTION METHOD THEREFOR, RESIN MOLDED BODY, PRODUCTION METHOD THEREFOR, | NITTO DENKO CORP | 2015-02-11 | — | — | CN | disclosed |
| CN-101522657-B | STAT3/5 activation inhibitor | OTSUKA PHARMACEUTICAL CO.,LTD. (JP) | 2014-10-15 | — | — | CN | disclosed |
| EP-1957073-B1 | MEDICINAL DRUG | OTSUKA PHARMA CO LTD (JP) | 2014-04-23 | — | — | EP | disclosed |
| WO-2007066784-A2 | DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-06-14 | — | — | WO | disclosed |
| EP-1773797-A2 | AROMATIC COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-04-18 | — | — | EP | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| WO-2006014012-A2 | AROMATIC COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-02-09 | — | — | WO | disclosed |
| CN-1705670-A | 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds | OTSUKA PHARMA CO LTD (JP) | 2005-12-07 | — | — | CN | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| EP-0450066-B1 | CARBOSTYRIL DERIVATIVES | OTSUKA PHARMA CO LTD (JP) | 1996-09-11 | — | — | EP | disclosed |
| US-5401740-A | FOR INHIBITING PLATELET AGGREGATION | OTSUKA PHARMACEUTICAL CO. (JP) | 1995-03-28 | — | — | US | disclosed |
| US-5227381-A | Anticoagulant | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-07-13 | — | — | US | disclosed |
| EP-0450066-A1 | CARBOSTYRIL DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-10-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | ESR1 1578/4885ADRA2A 746/4885SLC6A2 3396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.